Diabetic Retinopathy Market Size, Share & Trends Analysis Report By Type (Proliferative DR, Non-proliferative DR), By Management (Anti-VEGF Therapy, Vitrectomy), And Segment Forecasts, 2024 - 2030

Research Methodology

A three-pronged approach was followed for deducing the diabetic retinopathy market estimates and forecasts. The process has three steps: information procurement, analysis, and validation. The whole process is cyclical, and steps repeat until the estimates are validated. The three steps are explained in detail below:

Information procurement: Information procurement is one of the most extensive and important stages in our research process, and quality data is critical for accurate analysis. We followed a multi-channel data collection process for diabetic retinopathy market to gather the most reliable and current information possible.

• We buy access to paid databases such as Hoover’s and Factiva for company financials, industry information, white papers, industry journals, SME journals, and more.
• We tap into Grand View’s proprietary database of data points and insights from active and archived monitoring and reporting.
• We conduct primary research with industry experts through questionnaires and one-on-one phone interviews.
• We pull from reliable secondary sources such as white papers and government statistics, published by organizations like WHO, NGOs, World Bank, etc., Key Opinion Leaders (KoL) publications, company filings, investor documents, and more.
• We purchase and review investor analyst reports, broker reports, academic commentary, government quotes, and wealth management publications for insightful third-party perspectives.

Analysis: We mine the data collected to establish baselines for forecasting, identify trends and opportunities, gain insight into consumer demographics and drivers, and so much more. We utilized different methods of diabetic retinopathy market data depending on the type of information we’re trying to uncover in our research.

• Market Research Efforts: Bottom-up Approach for estimating and forecasting demand size and opportunity, top-down Approach for new product forecasting and penetration, and combined approach of both Bottom-up and Top-down for full coverage analysis.

• Value-Chain-Based Sizing & Forecasting: Supply-side estimates for understanding potential revenue through competitive benchmarking, forecasting, and penetration modeling.

• Demand-side estimates for identifying parent and ancillary markets, segment modeling, and heuristic forecasting.

• Qualitative Functional Deployment (QFD) Modelling for market share assessment.

Market formulation and validation: We mine the data collected to establish baselines for forecasting, identify trends and opportunities, gain insight into consumer demographics and drivers, and so much more. We utilize different methods of data analysis depending on the type of information we’re trying to uncover in our research.

• Market Formulation: This step involves the finalization of market numbers. This step on an internal level is designed to manage outputs from the Data Analysis step.

• Data Normalization: The final market estimates and forecasts are then aligned and sent to industry experts, in-panel quality control managers for validation.

• This step also entails the finalization of the report scope and data representation pattern.

• Validation: The process entails multiple levels of validation. All these steps run in parallel, and the study is forwarded for publishing only if all three levels render validated results.

Diabetic Retinopathy Market Categorization:

The diabetic retinopathy market was categorized into three segments, namely type (Proliferative Diabetic Retinopathy, Non-proliferative Diabetic Retinopathy), management (Anti-VEGF, Intraocular Steroid Injection, Laser Surgery, Vitrectomy), and regions (North America, Europe, Asia Pacific, Latin America, Middle East & Africa).

Segment Market Methodology:

The diabetic retinopathy market was segmented into type, management, and regions. The demand at a segment level was deduced using a funnel method. Concepts like the TAM, SAM, SOM, etc., were put into practice to understand the demand. We at GVR deploy three methods to deduce market estimates and determine forecasts. These methods are explained below:

Market research approaches: Bottom-up

• Demand estimation of each product across countries/regions summed up to from the total market.

• Variable analysis for demand forecast.

• Demand estimation via analyzing paid database, and company financials either via annual reports or paid database.

• Primary interviews for data revalidation and insight collection.

Market research approaches: Top-down

• Used extensively for new product forecasting or analyzing penetration levels.

• Tool used invoice product flow and penetration models Use of regression multi-variant analysis for forecasting Involves extensive use of paid and public databases.

• Primary interviews and vendor-based primary research for variable impact analysis.

Market research approaches: Combined

• This is the most common method. We apply concepts from both the top-down and bottom-up approaches to arrive at a viable conclusion.

Regional Market Methodology:

The diabetic retinopathy market was analyzed at a regional level. The global was divided into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa, keeping in focus variables like consumption patterns, export-import regulations, consumer expectations, etc. These regions were further divided into twenty-six countries, namely, the U.S.; Canada; the UK.; Germany; France; Italy; Spain; Denmark; Norway; Sweden; India; Singapore; South Korea; China; Japan; India; Australia; Thailand; South Korea; Brazil; Mexico; Argentina; South Africa; Saudi Arabia; UAE; Kuwait.

All three above-mentioned market research methodologies were applied to arrive at regional-level conclusions. The regions were then summed up to form the global market.

Diabetic retinopathy market companies & financials:

The diabetic retinopathy market was analyzed via companies operating in the sector. Analyzing these companies and cross-referencing them to the demand equation helped us validate our assumptions and conclusions. Key market players analyzed include:

• Bayer AG - Bayer AG is a pharmaceutical & chemical company. Its core businesses include healthcare products, biotechnology products, and agricultural chemicals. Bayer Healthcare, the pharmaceuticals division of Bayer AG, offers general and specialty medicines. The company operates through three segments— Crop Science, Pharmaceuticals, and Consumer Health.

• ABBVIE INC. - AbbVie Inc. is a global, diversified research-based biopharmaceutical firm with positions of leadership in immunology, oncology, esthetics, neurology, and eye care. In May 2020, AbbVie Inc. acquired Allergan plc, a specialty pharmaceutical company. Allergan plc is a multinational pharmaceutical firm that develops, manufactures, and sells generic pharmaceuticals. Medical esthetics and dermatology, plastic surgery, eye care, women's health, and anti-infective therapies are among the company's core business sectors.

• Novartis AG - Novartis AG is a multinational company catering to the pharmaceuticals market. It has a presence in over 140 countries. The company was formed following the merger of the agrochemical and pharmaceutical divisions of Sandoz Laboratories and Ciba-Geigy. It is a publicly held organization with five operating divisions—consumer health, Alcon, pharmaceuticals, Sandoz, and vaccines & diagnostics.

• Oxurion NV - Oxurion NV is a company focusing on biopharmaceutical products. The company specializes in manufacturing cancer and ophthalmic products. It has corporate offices in several countries, such as Ireland and the U.S. The company partners and collaborates with various clinical development organizations to develop innovative drugs for the treatment of eye diseases. The company has changed its corporate name from ThromboGenics to Oxurion NV.

• Sirnaomics Ltd. - Sirnaomics Ltd., Inc. is a privately held biopharmaceutical company that discovers & develops novel therapeutics. It uses small interfering Ribonucleic Acid (siRNA) technology and a nanoparticle drug delivery system to provide effective treatment for patients suffering from chronic diseases. The company has partnered with Guangzhou Xiangxue Pharmaceutical Co., Ltd. to develop and market innovative therapeutics worldwide. Sirnaomics Ltd. has subsidiaries in China at Guangzhou and Suzhou.

• Genentech, Inc. - Genentech, Inc. was established as a pioneer biotechnological company in 1976. In 2009, the company became a fully owned subsidiary of Roche and currently operates as an independent center for research and early development. It discovers and manufactures medicines for various chronic illnesses, such as carcinoma, immunological disorders, diabetes, neurological disorders, and infectious diseases. The company has over 11,300 patents to its name and currently employs more than 13,300 people. It has manufacturing facilities located in California and Oregon.

• Alimera Sciences - Alimera Sciences, founded by Dave Holland, Dan Myers, and Mark Testerman, is a public organization that develops ophthalmic products, especially for diseases affecting the retina or back of the eye. The company’s product portfolio comprises drugs used for the treatment of early as well as late-stage AMD, DME, and RVO.

• Ampio Pharmaceuticals Inc. - Ampio Pharmaceuticals is a publicly held organization that focuses on repurposing existing drugs in new therapeutic indications. The company’s portfolio comprises drugs for metabolic diseases, kidney disorders, inflammation, and eye care. It also manufactures diagnostic devices for the healthcare industry. Ampio Pharmaceuticals has over 180 patents to its name. This can be attributed to the strategic initiatives undertaken by the company, including innovative product development and clinical trials.

• BCN Peptides - BCN Peptides is a privately held organization that develops GMP-compliant bioactive peptides for various therapeutic applications. The company provides generic peptides, active pharmaceutical ingredients, and regulatory support. In addition, it offers products for the treatment of neurological, immunological, and inflammatory conditions, along with diabetes and cancer.

• Kowa Company, Ltd. - Kowa Company, Ltd. was established in 1894 in Japan as a wholesaler of cotton fabrics. Over a period of 120 years, it diversified & entered industries such as construction materials, textiles, textile machinery, environment & energy conserving, medicine manufacturing, and medical equipment. It operates several companies, namely, Kowa Pharmaceutical Co., Ltd; Kowa Eyecon Co., Ltd.; Kowa Shinyaku Co., Ltd.; Kowa Koga Factory Co., Ltd.; and Core Holding Co., Ltd. under its health & medical division. The group, through these affiliated companies, has dedicated its efforts toward the R&D, sales, manufacturing, and marketing of pharmaceutical products & medical devices, used for the treatment of lifestyle-related diseases, such as diabetes.

Value chain-based sizing & forecasting

Supply Side Estimates

• Company revenue estimation via referring to annual reports, investor presentations, and Hoover’s.

• Segment revenue determination via variable analysis and penetration modeling.

• Competitive benchmarking to identify market leaders and their collective revenue shares.

• Forecasting via analyzing commercialization rates, pipelines, market initiatives, distribution networks, etc.

Demand side estimates

• Identifying parent markets and ancillary markets

• Segment penetration analysis to obtain pertinent

• revenue/volume

• Heuristic forecasting with the help of subject matter experts

• Forecasting via variable analysis

Diabetic Retinopathy Market Report Objectives:

• Understanding market dynamics (in terms of drivers, restraints, & opportunities) in the countries.

• Understanding trends & variables in the individual countries & their impact on growth and using analytical tools to provide high-level insights into the market dynamics and the associated growth pattern.

• Understanding market estimates and forecasts (with the base year as 2023, historic information from 2018 to 2022, and forecast from 2024 to 2030). Regional estimates & forecasts for each category are available and are summed up to form the global market estimates.

Diabetic Retinopathy Market Report Assumptions:

• The report provides market value for the base year 2023 and a yearly forecast till 2030 in terms of revenue/volume or both. The market for each of the segment outlooks has been provided on region & country basis for the above-mentioned forecast period.

• The key industry dynamics, major technological trends, and application markets are evaluated to understand their impact on the demand for the forecast period. The growth rates were estimated using correlation, regression, and time-series analysis.

• We have used the bottom-up approach for market sizing, analyzing key regional markets, dynamics, & trends for various products and end-users. The total market has been estimated by integrating the country markets.

• All market estimates and forecasts have been validated through primary interviews with the key industry participants.

• Inflation has not been accounted for to estimate and forecast the market.

• Numbers may not add up due to rounding off.

• Europe consists of EU-8, Central & Eastern Europe, along with the Commonwealth of Independent States (CIS).

• Asia Pacific includes South Asia, East Asia, Southeast Asia, and Oceania (Australia & New Zealand).

• Latin America includes Central American countries and the South American continent

• Middle East includes Western Asia (as assigned by the UN Statistics Division) and the African continent.

Primary Research

GVR strives to procure the latest and unique information for reports directly from industry experts, which gives it a competitive edge. Quality is of utmost importance to us, therefore every year we focus on increasing our experts’ panel. Primary interviews are one of the critical steps in identifying recent market trends and scenarios. This process enables us to justify and validate our market estimates and forecasts to our clients. With more than 8,000 reports in our database, we have connected with some key opinion leaders across various domains, including healthcare, technology, consumer goods, and the chemical sector. Our process starts with identifying the right platform for a particular type of report, i.e., emails, LinkedIn, seminars, or telephonic conversation, as every report is unique and requires a differentiated approach.

We send out questionnaires to different experts from various regions/ countries, which is dependent on the following factors:

• Report/Market scope: If the market study is global, we send questionnaires to industry experts across various regions, including North America, Europe, Asia Pacific, Latin America, and MEA.

• Market Penetration: If the market is driven by technological advancements, population density, disease prevalence, or other factors, we identify experts and send out questionnaires based on region or country dominance.

The time to start receiving responses from industry experts varies based on how niche or well-penetrated the market is. Our reports include a detailed chapter on the KoL opinion section, which helps our clients understand the perspective of experts already in the market space.